What is needed is a well-powered, carefully controlled real-world trial of far-UVC that uses the number of infections as the primary outcome. Many researchers in the field agree with this need.
Only one such trial is currently ongoing, but more needs to be done
The link suggests that the estimated study completion date was April 30, 2023. I couldn’t find preliminary results anywhere but I found a talk about it here. It noted that they don’t expect Phase 2 –when they actually measure patient outcomes– to end until June 2025 and to only begin their statistical analysis then. (I think to ensure the study is still blinded?)
So still seems like some time to go before we hear about the results! Curious if you think that’s different.
You are correct that there are no results yet since the trial is still ongoing and double-blinded. I have talked to them about their trial and attended that talk. AFAIK they decided to extend the duration of the trial and are adding another study site (long-term care facility) since they received additional funding for a phase 2.
In this next phase of the trial, they will also be monitoring ozone and volatile organic compounds, which could provide some useful real-world data about those questions.
Thanks for such a great write-up!
The link suggests that the estimated study completion date was April 30, 2023. I couldn’t find preliminary results anywhere but I found a talk about it here. It noted that they don’t expect Phase 2 –when they actually measure patient outcomes– to end until June 2025 and to only begin their statistical analysis then. (I think to ensure the study is still blinded?)
So still seems like some time to go before we hear about the results! Curious if you think that’s different.
(The linked talk was part of the 1st International Congress on Far-UVC Science and Technology, who have uploaded all their videos on their website. A lot of them see very interesting for more details!)
Thanks, Luca!
You are correct that there are no results yet since the trial is still ongoing and double-blinded. I have talked to them about their trial and attended that talk. AFAIK they decided to extend the duration of the trial and are adding another study site (long-term care facility) since they received additional funding for a phase 2.
In this next phase of the trial, they will also be monitoring ozone and volatile organic compounds, which could provide some useful real-world data about those questions.